Originally published as JCO Early Release 10.1200/JCO.2005.04.3810 on May 8 2006

This Article Full Text Full Text (PDF) Publisher's Note Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linden, H. M. Articles by Mankoff, D. A. Search for Related Content PubMed PubMed Citation Articles by Linden, H. M. Articles by Mankoff, D. A.

Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer

Hannah M. Linden, Svetlana A. Stekhova, Jeanne M. Link, Julie R. Gralow, Robert B. Livingston, Georgiana K. Ellis, Philip H. Petra, Lanell M. Peterson, Erin K. Schubert, Lisa K. Dunnwald, Kenneth A. Krohn, David A. Mankoff

From the Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance; Division of Nuclear Medicine; and the Department of Biochemistry, University of Washington School of Medicine, Seattle, WA

Address reprint requests to Hannah M. Linden, MD, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Ave East, Seattle, WA 98109; e-mail: hmlinden{at}u.washington.edu

PURPOSE: In breast cancer, [¹⁸F]fluoroestradiol (FES) positron emission tomography (PET) correlates with estrogen receptors (ER) expression and predicts response to tamoxifen. We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors.

PATIENTS AND METHODS: Initial FES uptake measurements in 47 patients with ER-positive tumors were correlated with subsequent tumor response to 6 months of hormonal treatment. Most patients had bone dominant disease and prior tamoxifen exposure. Response was compared to initial FES-PET uptake, measured qualitatively and quantitatively using standardized uptake value (SUV) and estradiol-binding flux.

RESULTS: Eleven of 47 patients (23%) had an objective response. While no patients with absent FES uptake had a response to treatment, the association between qualitative FES-PET results and response was not significant (P = .14). However, quantitative FES uptake and response were significantly associated; zero of 15 patients with initial SUV less than 1.5 responded to hormonal therapy, compared with 11 of 32 patients (34%) with SUV higher than 1.5 (P < .01). In the subset of patients whose tumors did not overexpress HER2/neu, 11 of 24 patients (46%) with SUV higher than 1.5 responded.

CONCLUSION: Quantitative FES-PET can predict response to hormonal therapy and may help guide treatment selection. Treatment selection using quantitative FES-PET in our patient series would have increased the rate of response from 23% to 34% overall, and from 29% to 46% in the subset of patients lacking HER2/neu overexpression. A multi-institutional collaborative trial would permit definitive assessment of the value of FES-PET for therapeutic decision making.

Supported by NIH Grants No. P01CA42045, R01CA72064, S10 RR17229, and the Avon Foundation.

Presented in part at the 51st Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA, June 19-23, 2004.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				T. Tsujikawa, Y. Yoshida, T. Mori, T. Kurokawa, Y. Fujibayashi, F. Kotsuji, and H. Okazawa Uterine Tumors: Pathophysiologic Imaging with 16{alpha}-[18F]fluoro-17{beta}-estradiol and 18F Fluorodeoxyglucose PET--Initial Experience Radiology, August 1, 2008; 248(2): 599 - 605. [Abstract] [Full Text] [PDF]

				T. K. Nayak, H. J. Hathaway, C. Ramesh, J. B. Arterburn, D. Dai, L. A. Sklar, J. P. Norenberg, and E. R. Prossnitz Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers J. Nucl. Med., June 1, 2008; 49(6): 978 - 986. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				L. M. Peterson, D. A. Mankoff, T. Lawton, K. Yagle, E. K. Schubert, S. Stekhova, A. Gown, J. M. Link, T. Tewson, and K. A. Krohn Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol J. Nucl. Med., March 1, 2008; 49(3): 367 - 374. [Abstract] [Full Text] [PDF]

				A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813. [Abstract] [Full Text] [PDF]

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]

				D. A. Torigian, S. S. Huang, M. Houseni, and A. Alavi Functional Imaging of Cancer with Emphasis on Molecular Techniques CA Cancer J Clin, July 1, 2007; 57(4): 206 - 224. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				J. G. Rajendran and D. A. Mankoff Beyond Detection: Novel Applications for PET Imaging to Guide Cancer Therapy J. Nucl. Med., June 1, 2007; 48(6): 855 - 856. [Full Text] [PDF]

				H. Zhang, A. M. Pelzer, D. T. Kiang, and D. Yee Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin Cancer Res., January 1, 2007; 67(1): 391 - 397. [Abstract] [Full Text] [PDF]